Search research articles
Contact Us
Filters
Showing results (351-360 of 366) with videos related to
Page
of 37
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2010
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial
M Kaufmann, N Maass, S D Costa, et al.
Zentralblatt Fur Gynakologie
|
December 26, 2001
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group]
G von Minckwitz, G Raab, M Schütte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B Gerber, S Loibl, H Eidtmann, et al.
Zentralblatt Fur Gynakologie
|
September 17, 2002
[Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast]
G Von Minckwitz, S D Costa, K Brunnert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
G von Minckwitz, M Rezai, P A Fasching, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2013
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
C Denkert, S Loibl, B M Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
G von Minckwitz, M Rezai, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
J L Lindner, S Loibl, C Denkert, et al.
Geburtshilfe Und Frauenheilkunde
|
July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
M Untch, N Harbeck, J Huober, et al.
Page
of 37
Search research articles
Search
Showing results (351-360 of 366) with videos related to
Sort By:
Page
of 37
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2010
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial
M Kaufmann, N Maass, S D Costa, et al.
Zentralblatt Fur Gynakologie
|
December 26, 2001
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group]
G von Minckwitz, G Raab, M Schütte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B Gerber, S Loibl, H Eidtmann, et al.
Zentralblatt Fur Gynakologie
|
September 17, 2002
[Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast]
G Von Minckwitz, S D Costa, K Brunnert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
G von Minckwitz, M Rezai, P A Fasching, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2013
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
C Denkert, S Loibl, B M Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
G von Minckwitz, M Rezai, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
J L Lindner, S Loibl, C Denkert, et al.
Geburtshilfe Und Frauenheilkunde
|
July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
M Untch, N Harbeck, J Huober, et al.
Page
of 37